Mergers and Acquisitions in the Global Life Sciences Industry, 2018
Mergers and Acquisitions in the Global Life Sciences Industry, 2018
M&As for Growth in Patient Engagement, Artificial Intelligence and Big Data Analytics are Driving Greater Vertical Integration
07-Mar-2019
North America
Description
The Healthcare industry has witnessed some of the largest mega-mergers in 2018 – mergers on the provider as well as the payer ends. While this has the potential to bring a shift in power centers in the ecosystem, each stakeholder has relied heavily on inorganic growth to maintain their stronghold. This Mergers and Acquisitions in Life Sciences Industry report provide details of the latest merger and acquisition (M&A) agreements announced in the pharmaceutical, biotechnology, contract services diagnostic, and other life science sectors.
Research Highlights
The report provides a detailed understanding and analysis of how and why companies enter M&A deals, which legislative and regulatory policies are promoting M&A activities, and how APAC investors are growing their presence in developed economies, undeterred by policy uncertainties. It also highlights the growing influence of non-traditional players in the life science space and their impact in steering the direction of M&A activity of the traditional players. It further brings out the growing acceptance of digital revenue streams, an under-explored opportunity in connected health. The exponential growth of private equity (PE) investors, and their appetite to invest in high-risk areas, has also allowed unlocking of the potential of several new technologies, creating a ripe environment for corporate acquisitions. At the same time, PE investors’ ability to bid for higher value deals has created competition for the same targets, often outbidding corporate investors.
This study dives deeper into each stakeholder segment to uncover their unique M&A dynamics and chart the activity of top 10 companies in each segment. Several biopharma companies have relied on smaller acquisitions to bolster their R&D pipelines, whereas several others have sought high-value deals to merge or acquire competitor companies in order to achieve critical mass in R&D and ensure continued growth and dominance in the global marketplace. Contract service organizations (CSO) are experiencing the highest rate of consolidation, with the goal of emerging as one-stop-shop solution providers. However, CSOs will soon have to think beyond mere capacity expansion and acquire targets specialized in tangential services like supply chain and patient connectedness. Diagnostic and research tool (DRT) OEMs have experienced a different M&A trend and will have to rely more on value-add services to overcome the slump in M&A derived growth. Strategic imperatives for companies to recalibrate their business models and be future ready are provided in this study as well. Finally, the study also briefly covers growing trends in the outsourcing of innovation, production and selling, and the heightened importance of innovation hubs in promoting M&A.
Key Issues Addressed
- Which are the emerging power centers as a result of consolidation? Is there a shift in bargaining power?
- What region-specific factors are prompting M&A? Which regions are experiencing maximum inbound and outbound deals?
- Is the current rate of M&A sustainable? What will be the rate of shift towards outsourcing?
- What will be the impact of external disruptors like FAMGA on the direction of acquisitions?
- Which stakeholders are experiencing the maximum positive and negative impact of M&A?
- How are mid-sized companies aligning their strategies to survive in this increasingly consolidating space?
Author: Khushbu Jain
Table of Contents
Key Findings
Key Questions this Study will Answer
Big Market Themes
M&A Stakeholder Opportunity Heat Map
Major Growth Opportunities
Strategic Imperatives for the Life Sciences Industry
Scope and Segmentation
Methodology and Assumptions
Methodology and Assumptions (continued)
Regulatory and Legislative Changes Impacting M&A
Non-Traditional Players—Infusing Competition into Traditional Markets
FAMGA* M&A Activity—Comparison with Traditional Healthcare Players
Growing PE Ownership in the Healthcare Space
Growing PE Ownership in the Healthcare Space (continued)
Healthcare M&A Activity
Geographic Distribution of Targets
Market Attractiveness for M&A
Notable M&A Deals
Active Participants in the M&A Landscape
Pharma and Biopharma M&A Activity
Factors Impacting M&A
Roche Case Study—M&A to Create End-to-End Precision Medicine Portfolio
Activity Profile of Top 10 Pharma Companies
Connected Health—From Patient Communication to Engagement
Growth Opportunity 1—Patient Engagement 2.0
Pharmaceutical Companies Can Engage Patients Throughout the Drug Discovery and Development Cycle
Emerging M&A Opportunity Areas
CRO Industry M&A Activity
Eurofins Scientific Case Study—M&A Story of an Emerging Competitor
Activity Profile of Top 10 CRO Companies
Clinical Trial Recruitment and Retention Challenge for CROs
Growth Opportunity 2—Clinical Trial Recruitment and Retention
CDMO Industry M&A Activity
Thermo Fisher and Patheon—Redefining One-stop-shop
Activity Profile of Top 10 CDMO Companies
Will M&A Address the Size Challenge?
Growth Opportunity 3—Cell and Gene Therapy
DRT Industry M&A Activity
Factors Impacting M&A
Invitae Case Study—Genetic Information Company
Activity Profile of Top 10 DRT Companies
A Very Active PE Landscape—Increasing Valuations
Rising Valuations—A New Challenge for M&A
Growth Opportunity 4—Insight-as-a-Service
Concluding Thoughts
Top 3 Predictions
Legal Disclaimer
M&A and Collaboration Drivers
Top Technologies Attracting PE Investment
Collaboration Assessment
Collaboration Assessment (continued)
Collaboration Assessment (continued)
Collaboration Assessment (continued)
Collaboration Assessment (continued)
List of Exhibits
List of Exhibits (continued)
The Frost & Sullivan Story
Value Proposition—Future of Your Company & Career
Global Perspective
Industry Convergence
360º Research Perspective
Implementation Excellence
Our Blue Ocean Strategy
Popular Topics
Research Highlights
The report provides a detailed understanding and analysis of how and why companies enter M&A deals, which legislative and regulatory policies are promoting M&A activities, and how APAC investors are growing their presence in developed economies, undeterred by policy uncertainties. It also highlights the growing influence of non-traditional players in the life science space and their impact in steering the direction of M&A activity of the traditional players. It further brings out the growing acceptance of digital revenue streams, an under-explored opportunity in connected health. The exponential growth of private equity (PE) investors, and their appetite to invest in high-risk areas, has also allowed unlocking of the potential of several new technologies, creating a ripe environment for corporate acquisitions. At the same time, PE investors’ ability to bid for higher value deals has created competition for the same targets, often outbidding corporate investors.
This study dives deeper into each stakeholder segment to uncover their unique M&A dynamics and chart the activity of top 10 companies in each segment. Several biopharma companies have relied on smaller acquisitions to bolster their R&D pipelines, whereas several others have sought high-value deals to merge or acquire competitor companies in order to achieve critical mass in R&D a
No Index | No |
---|---|
Podcast | No |
Author | Khushbu Jain |
Industries | Healthcare |
WIP Number | MEA4-01-00-00-00 |
Is Prebook | No |
GPS Codes | 9564-B1,9575-B1,9600-B1,9612-B1,9A56-B1,9562-B1,9571-B1,9573-B1,99BC-B1,99C1-B1,99C6-B1,9568-B1,9611-B1,9627-B1 |